Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

NEXT STORY
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference
PREV STORY
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021

author_avatar
NASDAQ Market News

HalioDx performed development work for ipsogen® JAK2 510(k) clearance by QIAGEN

HalioDx performed development work for ipsogen® JAK2 510(k) clearance by QIAGEN               HalioDx has ...

author_avatar
NASDAQ Market News

FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer

author_avatar
NASDAQ Market News